Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Renal insufficiency

Renal insufficiency

Part of Kidney Diseases

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Renal insufficiency

32 trials tracked for Renal insufficiency: 5 in phase 3 or 4 and 1 with published results. The most-cited published study has 101 citations.

32Trials tracked
5Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 3 Phase 3 2 Phase 2 3 Phase 1 18 Other / NA 6
  1. Phase 4 Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency Completed · 101 cited
  2. Phase 4 Renal Safety Evaluation After Dotarem®-Enhanced MRI Completed
  3. Phase 4 Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI) Completed
  4. Phase 3 An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment Completed
  5. Phase 3 Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment Completed
  6. Phase 2 Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction Completed
Show 26 more trials
  1. Phase 2 A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated Completed
  2. Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function Completed
  3. Phase 1 A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems Completed
  4. Phase 1 Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386) Completed
  5. Phase 1 Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067) Completed
  6. Phase 1 A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems Completed
  7. Phase 1 The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026) Completed
  8. Phase 1 Afatinib in Subjects With Kidney Dysfunction Completed
  9. Phase 1 Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants Completed
  10. Phase 1 Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment Completed
  11. Phase 1 Renal Allograft Tolerance Through Mixed Chimerism (Belatacept) Completed
  12. Phase 1 A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems Completed
  13. Phase 1 A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body Completed
  14. Phase 1 PF-04634817 Renal Impairment Study Completed
  15. Phase 1 Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105) Completed
  16. Phase 1 A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function Completed
  17. Phase 1 PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers Completed
  18. Phase 1 Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment Completed
  19. Phase 1 Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655) Completed
  20. Phase 1 A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function Completed
  21. N/A Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist Completed
  22. N/A Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants Completed
  23. N/A XIENCE 28 USA Study Completed
  24. N/A Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation Completed
  25. N/A XIENCE 28 Global Study Completed
  26. N/A Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Renal insufficiency: what the trials found

Newer clinical evidence demonstrates that BI 10773 significantly reduces HbA1c levels in patients with mild or moderate renal impairment compared to placebo (p<0.0001) 5. Specifically, significant reductions were observed in both the mild renal impairment subgroup (p<0.0001) and the moderate renal impairment subgroup (p<0.0001) 5.

Canagliflozin has been shown to significantly reduce Fasting Plasma Glucose (FPG) from baseline at week 26 (p=0.021) 6. While Canagliflozin also resulted in a statistically significant reduction in HbA1c at week 26 compared to placebo (p=0.012), the difference in the percentage of patients achieving an HbA1c <7% at week 26 did not reach statistical significance (p=0.227) 6.

Recent results — preliminary, needs further review

  • * BI 1015550 was evaluated in a Phase 1 trial 10. * Selpercatinib showed that approximately 4.8% to 10.1% of the administered dose was excreted in urine during a Phase 1 study 11.

For the clinician treating this condition

  • BI 10773 is effective for HbA1c reduction in patients with mild to moderate renal impairment 5.
  • Canagliflozin significantly reduces Fasting Plasma Glucose at week 26, though it did not show a statistically significant difference in the proportion of patients reaching an HbA1c <7% compared to placebo 6.

AI synthesis of 4 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Surgical treatment for gouty tophi wounds associated with high healing rates in retrospective study
Orthopedics & Sports Medicine Cohort
Surgical treatment for gouty tophi wounds associated with high healing rates in retrospective study Surgery may help heal gouty tophi wounds
This retrospective cohort study of 130 patients with gouty tophi wounds in China observed high wound healing rates following surgical interv…
A small study shows that surgical treatment, including wound cleaning and vacuum drainage, helped most patients with gouty tophi wounds heal…
Frontiers Apr 30, 2026

Research across Kidney Diseases

Related studies from across the Kidney Diseases family.

Environmental cadmium exposure may cause male reproductive dysfunction through the renal-testis axis
Psychiatry Sys. Review
Environmental cadmium exposure may cause male reproductive dysfunction through the renal-testis axis Cadmium exposure may harm male fertility and kidney health
This narrative review of 40 animal studies synthesizes evidence on environmental cadmium exposure and its impact on male reproduction. The a…
Environmental cadmium exposure can damage the male reproductive system and kidneys, potentially leading to lower semen quality and other iss…
Frontiers Jul 24, 2026
Programmed cell death pathways form a spatiotemporally regulated network driving tubular damage in renal IRI
Allergy & Immunology Sys. Review
Programmed cell death pathways form a spatiotemporally regulated network driving tubular damage in renal IRI New research identifies key pathways driving acute kidney injury
This systematic review examines the roles of pyroptosis, ferroptosis, cuproptosis, and necroptosis as key mediators of inflammation and oxid…
Researchers have mapped out a complex network of cell death pathways that drive inflammation and damage in patients with acute kidney injury…
Frontiers Jun 18, 2026
Fluoroless ultrasound-guided techniques lower complications in percutaneous nephrolithotomy with equivalent stone-free rates
Urology Meta-analysis
Fluoroless ultrasound-guided techniques lower complications in percutaneous nephrolithotomy with equivalent stone-free rates Fluoroless ultrasound guidance reduces complications during kidney stone surgery
This systematic review and meta-analysis of randomized studies evaluated fluoroless ultrasound-guided versus fluoroscopy-guided techniques f…
A meta-analysis of randomized trials shows that using ultrasound instead of X-ray guidance lowers overall complications for kidney stone rem…
Jun 1, 2026
Meta-analysis of RCTs shows mPCNL yields higher single-session stone-free rates than RIRS for medium renal stones
Urology Meta-analysis
Meta-analysis of RCTs shows mPCNL yields higher single-session stone-free rates than RIRS for medium renal stones Mini-PCNL clears kidney stones better than RIRS in one session
This meta-analysis of randomized controlled trials evaluated retrograde intrarenal surgery versus miniaturized percutaneous nephrolithotomy …
Mini-PCNL clears medium-sized kidney stones in one session more often than RIRS, but RIRS has fewer complications and shorter hospital stays…
May 24, 2026
Narrative review on anthracycline cardiorenal toxicity and dexrazoxane protection
Cardiology Sys. Review
Narrative review on anthracycline cardiorenal toxicity and dexrazoxane protection Doctors seek better ways to protect heart and kidney health during cancer drug treatment
This narrative review synthesizes evidence on anthracycline-induced cardiorenal toxicity and dexrazoxane's protective role. The authors note…
Cancer treatments called anthracyclines can harm the heart and kidneys. This review explains why doctors need new strategies to keep patient…
Frontiers May 15, 2026
Narrative review discusses exosomes for renal ischemia-reperfusion injury management and translational barriers
Drug Pipeline Sys. Review
Narrative review discusses exosomes for renal ischemia-reperfusion injury management and translational barriers Tiny Kidney Protectors May Shield Patients From Sudden Damage
This narrative review examines the potential of exosomes for managing renal ischemia-reperfusion injury. The authors discuss the scope of th…
• Exosomes might prevent kidney harm when blood flow returns • Helps surgery patients and trauma survivors avoid kidney failure • Still in l…
Frontiers May 12, 2026
Meta-analysis links suprarenal aortic repair techniques to higher risk of permanent renal dialysis in AAA patients
Nephrology Meta-analysis
Meta-analysis links suprarenal aortic repair techniques to higher risk of permanent renal dialysis in AAA patients Large review shows kidney dialysis risk is higher when surgeons clamp above the kidney during aortic repair
This systematic review and meta-analysis evaluated the risk of permanent renal dialysis following various abdominal aortic aneurysm repair t…
A big study looked at over 72,000 patients having surgery for a bulging aorta. It found that operations touching the kidney area make kidney…
May 8, 2026
Narrative review on renal involvement in primary Sjögren's disease and therapeutic prospects
Allergy & Immunology Sys. Review
Narrative review on renal involvement in primary Sjögren's disease and therapeutic prospects Understanding kidney problems in primary Sjogren's disease patients needs more research
This narrative review synthesizes current knowledge on renal involvement in primary Sjögren's disease. It highlights that the pathogenic bas…
Doctors are still learning how kidneys get hurt in primary Sjogren's disease. Current treatments work by guesswork because the exact cause i…
Frontiers May 8, 2026
Narrative review offers theoretical basis for selecting biologic therapies in psoriasis patients with renal concerns
Dermatology Sys. Review
Narrative review offers theoretical basis for selecting biologic therapies in psoriasis patients with renal concerns New Psoriasis Treatments May Protect Kidneys While Fighting Skin Flares
This narrative review examines the use of TNF-alpha, IL-17, and IL-12/23 inhibitors in psoriasis patients with renal concerns. The authors p…
• Some biologics shield kidneys from damage during psoriasis treatment • Helps the 8 million Americans with psoriasis and kidney worries • N…
Frontiers May 5, 2026
Patient-specific 3D printed kidney models improved comprehension and satisfaction compared to conventional 2D CT scans in PCNL patients
Urology RCT
Patient-specific 3D printed kidney models improved comprehension and satisfaction compared to conventional 2D CT scans in PCNL patients 3D kidney models improve patient understanding before surgery
This randomized clinical study enrolled 40 individuals aged 18 to 80 planned for PCNL surgery.
A small study found that 3D printed kidney models significantly improved patient comprehension and satisfaction compared to standard 2D scan…
May 1, 2026
Retrospective cohort study links PPI use to drug-related problems in hospitalized renal disease patients
Drug Pipeline Cohort
Retrospective cohort study links PPI use to drug-related problems in hospitalized renal disease patients Nearly half of hospitalized kidney patients had drug problems linked to stomach acid reducers
This retrospective cohort study evaluated 520 hospitalized internal nephrology inpatients to assess drug-related problems (DRPs) associated …
Nearly half of hospitalized kidney patients faced drug problems linked to stomach acid reducers. Other medicines and dialysis types also rai…
Frontiers Apr 30, 2026
Narrative review discusses renal risks in inflammatory bowel disease patients
Nephrology Sys. Review
Narrative review discusses renal risks in inflammatory bowel disease patients Kidney risks for people with inflammatory bowel disease remain unclear and need more study
This narrative review examines renal complications in individuals with inflammatory bowel disease.
People with inflammatory bowel disease face kidney risks, but current evidence relies on animal studies and lacks human proof.
Frontiers Apr 29, 2026